Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice

References

• Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
   PubMed Web of Science ®Google Scholar
• Mazanec DJ, Podichetty VK, Mompoint A, et al. Vertebral compression fractures: manage aggressively to prevent sequelae. Cleve Clin J Med 2003;70:147-56
   PubMed Web of Science ®Google Scholar
• Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999;159:1215-20
   PubMed Web of Science ®Google Scholar
• Ross PD, Davis JW, Epstein RS, et al. Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol 1994;47:231-9
   PubMed Web of Science ®Google Scholar
• Ulivieri FM. Back pain treatment in post-menopausal osteoporosis with vertebral fractures. Aging Clin Exp Res 2007;19:21-3
   PubMedGoogle Scholar
• Nevitt MC, Chen P, Dore RK, et al. Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:273-80
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Nevitt MC, et al. Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1992;7:449-56
   PubMed Web of Science ®Google Scholar
• Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255-62
   PubMed Web of Science ®Google Scholar
• Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384-92
   PubMed Web of Science ®Google Scholar
• Silverman SL, Minshall ME, Shen W, et al. Health-related quality of life subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001;44:2611-19
   PubMed Web of Science ®Google Scholar
• Silverman SL, Piziak VK, Chen P, et al. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005;32:2405-9
   PubMed Web of Science ®Google Scholar
• Burger H, Van Daele PL, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997;12:152-7
   PubMed Web of Science ®Google Scholar
• Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996;156:2469-75
   PubMed Web of Science ®Google Scholar
• Ross PD. Clinical consequences of vertebral fractures. Am J Med 1997;103:30S-42S
   PubMedGoogle Scholar
• Francis RM, Aspray TJ, Hide G, et al. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008;19:895-903
   PubMed Web of Science ®Google Scholar
• Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006;54:782-9
   PubMed Web of Science ®Google Scholar
• Genant HK, Halse J, Briney WG, et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005;21:1027-34
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Black DM, Palermo L, Nevitt MC, et al. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:90-101
   PubMed Web of Science ®Google Scholar
• Pluijm SM, Tromp AM, Smit JH, et al. Consequences of vertebral deformities in older men and women. J Bone Miner Res 2000;15:1564-72
   PubMed Web of Science ®Google Scholar
• Miller PD, Shergy WJ, Body JJ, et al. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005;32:1556-62
   PubMed Web of Science ®Google Scholar
• Lems WF, Karras D, Langdahl BL, et al. Fracture incidence, quality of life and back pain in women with osteoporosis and concomitant glucocorticoid use treated with teriparatide: 18-month results from the European Forsteo Observational Study. Bone 2009;44:s448-9
   Google Scholar
• Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93
   PubMed Web of Science ®Google Scholar
• Lau AN, Ali SH, Sawka AM, et al. Improvement in health-related quality of life in osteoporosis patients treated with teriparatide. BMC Musculoskelet Disord 2008;9:151
   PubMed Web of Science ®Google Scholar
• Lyritis G, Marin F, Barker C, et al. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr Med Res Opin 2010;26:1799-807
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Palermo L, et al. Kyphosis in older women and its relation to back pain, disability and osteopenia: the study of osteoporotic fractures. Osteoporos Int 1994;4:55-60
   PubMed Web of Science ®Google Scholar
• EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208
   Google Scholar
• Szende A, Williams A, eds. Measuring Self-Reported Population Health: an International Perspective Based on EQ-5D. Budapest: SpringMed Publishing, 2004
   Google Scholar
• Tosteson AN, Hammond CS. Quality-of-life assessment in osteoporosis, health-status and preference-based measures. Pharmacoeconomics 2002;20:289-303
   PubMed Web of Science ®Google Scholar
• Cockerill W, Lunt M, Silman AJ, et al. Health related quality of life and radiographic vertebral fracture. Osteoporos Int 2004;15:113-19
   PubMed Web of Science ®Google Scholar
• Faries DE, Obenchain RL, Haro JM, et al. Analysis of observational health care data using SAS. SAS Institute Inc., Cary, NC, USA, 2010
   Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 2007;41:308-17
   PubMed Web of Science ®Google Scholar
• Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008;24:377-84
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000;160:77-85
   PubMed Web of Science ®Google Scholar
• Majima T, Shimatsu A, Komatsu Y, et al. Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study. J Bone Miner Metab 2009;27:168-74
   PubMed Web of Science ®Google Scholar
• O’Neill TW, Cockerill W, Matthis C, et al. Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporos Int 2004;15:760-5
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Chen P, Kiel DP, et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:1630-7
   PubMed Web of Science ®Google Scholar